ArticleAnnals of medicine and surgery (2012)2025
Enhertu as an effective treatment for metastatic lung cancer with brain metastasis recurrence: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic lung cancer with recurrent brain metastasis presents significant treatment challenges. Enhertu (trastuzumab deruxtecan), a targeted therapy for HER2-positive cancers, has shown promise in treating solid tumors, including nonsmall cell lung cancer (NSCLC) with brain metastases. This case report examines the efficacy of Enhertu in a patient with metastatic lung cancer and recurrent brain metastasis. Case presentation: A 39-year-old woman diagnosed with Stage IV adenocarcinoma of the left lung, negative for EGFR, ALK, and ROS-1, but with an ERBB2 mutation, experienced neurological symptoms leading to a diagnosis of brain metastasis in 2019. After multiple lines of therapy, including surgery, irradiation, chemotherapy, and targeted treatments, she presented with recurrent brain metastasis in January 2024. Following progression despite previous treatments, she was started on Enhertu in February 2024. Intervention: The patient was treated with Enhertu, and after six cycles, radiologic evaluation via PET and MRI scans in June 2024 demonstrated significant reduction in the size of cerebral and cerebellar metastases, with no new lesions or abnormal meningeal enhancement. Additionally, there was notable regression in the size and metabolic activity of lung lesions and previously hypermetabolic nodes. Results: Enhertu led to a partial response, with regression of most metastatic sites, including brain and lung metastases, and no evidence of new hypermetabolic lesions. The treatment was well tolerated with minimal adverse effects. Conclusion: Enhertu represents a promising treatment option for HER2-mutant metastatic lung cancer with recurrent brain metastasis. This case highlights the potential of Enhertu in overcoming treatment resistance in complex metastatic settings, warranting further investigation in broader clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.